Patient trajectories among hospitalised COVID-19 patients vaccinated with an mRNA vaccine in Norway: a register-based cohort study

Supplementary materials A

## 1. Information on the data sources

The data used in this study came from the Norwegian national emergency preparedness register, Beredt C19, which contains individual-level data from central health registries, national clinical registries and other national administrative registries. More information on Beredt C19 is available here: <https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>.

### 1.1 Data source of hospitalised patients: the Norwegian Intensive Care and Pandemic Registry

The Norwegian Intensive Care and Pandemic Registry (NIPaR) is a national clinical registry that was expanded to include COVID-19 patients in conjunction with the COVID-19 pandemic. In the registry, all patients who have tested positive for SARS-CoV-2 and are admitted to hospital are registered. All Norwegian hospitals report to NIPaR, and reporting is mandatory. For patients who contracted SARS-CoV-2 while admitted to hospital, the time of admission is set to the date of symptom onset, or date of sampling if the patient is asymptomatic. The date of discharge for these patients is registered as when they recovered from COVID-19, even if they are still admitted to hospital for other causes. Patients who are readmitted to hospital without symptoms are only registered if they test positive for SARS-CoV-2 again and are isolated, or if a new test is not taken and the patient is isolated. Patients who are readmitted to hospital are not registered if they have tested negative for SARS-CoV-2, test positive but do not require isolation, or a new test is not taken, and the patient is not isolated. In addition, patients who are admitted to hospital for long-term complications of COVID-19 are registered if less than three months has passed since positive test. The reported main cause of hospitalisation is a clinical assessment. For patients reported with a different main cause than COVID-19, we cannot rule out that COVID-19 may have been a contributing factor for admission. In NIPaR, underlying risk factors for severe COVID-19 diagnosed before admission are registered. The following risk factors are registered; asthma, cancer, chronic lung disease, chronic neurological or neuromuscular disease, diabetes (type 1 and 2), heart disease including hypertension, immunocompromised including HIV and immunosuppressive treatment, kidney disease including kidney failure, liver disease including liver failure, pregnancy, current smoker and body mass index (calculated as weight in kilograms divided by height in centimetres squared). For cancer, only active cancer is registered, meaning cancer where the patient still receives treatment, or regular control (>1 per year). Other well-regulated or treated conditions are not distinguished from unregulated or untreated conditions, for example asthma. Full details on the registration of hospitalised patients are available here (in Norwegian): <https://helse-bergen.no/norsk-pandemiregister/registrering-i-norsk-pandemiregister-informasjon-til-ansatte>

NIPaR also includes data on patients who have tested positive for SARS-CoV-2 and are admitted to an intensive care unit (ICU). Patients are registered as ICU patients if they fulfil one of five categories:

1. Length of stay over 24 hours in intensive care
2. Require mechanical ventilation
3. Are transferred between intensive care wards
4. Persistent administration of vasoactive medication
5. Length of stay under 24 hours, but passed away during stay in intensive care

Full details on the registration of intensive care patients are available here (in Norwegian): <https://helse-bergen.no/norsk-intensivregister-nir/korona-pa-intensiv/hvordan-registrere-covid-19>

### 1.2 Other registries included in the study

We included data on notified cases of laboratory-confirmed SARS-CoV-2 infection from the Norwegian Surveillance System for Communicable Diseases (MSIS). Data on virus variants came from the MSIS laboratory database (national laboratory database), which receives SARS-CoV-2 test results from all Norwegian microbiology laboratories. The laboratory testing for variants of SARS-CoV-2 in Norway has been described in detail elsewhere (1, 2). Data on COVID-19 vaccinations came from the Norwegian Immunisation Registry, SYSVAK. Data on persons with a national identity number was drawn from the national population registry. The national identity number was essential to link data from all registries used in the analysis.

## 2. Sensitivity analyses

In addition to the main analysis, we conducted sensitivity analyses by changing the definition of our study population, time period of analysis (to take into account progression of the vaccination programme in different age groups (3)) or our outcome definitions to further explore if our main results were robust. The adjusted estimates from our sensitivity analyses are presented in Table S1. The methodology used was the same as the one used in the main analysis (see manuscript and supplementary material D).

*Table S1. Sensitivity analyses with adjusted hazard ratios for discharge from hospital with and without stay in intensive care (Cox proportional hazards model) and adjusted odds ratio for intensive care admission and in-hospital death (logistic regression), by vaccination status and age group, Norway, 1 February – 30 September 2021.*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | Days in hospital including patients admitted to ICU | | Days in hospital for patients not admitted to ICU | | Admission to ICU | | Death in hospital a | |
| Age group | Vaccination status | Number of patients | Adjusted hazard ratio for discharge (95%CI) | Number of patients | Adjusted hazard ratio for discharge (95%CI) | Yes | Adjusted odds ratio (95%CI) | Yes | Adjusted odds ratio (95%CI) |
| Study time period April to September, instead of February to September (vaccination in Norway was underway in all age groups ≥65 years in mid-March) | | | | | | | | | |
| 65–79 years | Unvaccinated | 176 | Ref | 132 | Ref | 44 | Ref | 16 | Ref |
| Fully vaccinated | 57 | 1.386 (0.976–1.968) | 47 | 1.052 (0.749–1.477) | 10 | 0.580 (0.252–1.228) | 7 | 0.836 (0.279–2.299) |
| Partially and fully vaccinated | 78 | 1.243 (0.928–1.666) | 66 | 1.098 (0.802–1.502) | 12 | 0.522 (0.247–1.036) | 10 | 0.954 (0.370–2.356) |
| 18–79 years | Unvaccinated | 1156 | Ref | 955 | Ref | 201 | Ref | 29 | Ref |
| Fully vaccinated | 106 | **1.348 (1.051–1.727)** | 86 | 1.183 (0.903–1.551) | 20 | **0.402 (0.207–0.752)** | 12 | 1.201 (0.514–2.654) |
| Partially and fully vaccinated | 170 | **1.469 (1.208–1.788)** | 145 | **1.263 (1.019–1.565)** | 25 | **0.358 (0.201–0.615)** | 16 | 1.138 (0.533–2.344) |
| Study time period July to September, instead of February to September (vaccination in Norway was underway in all age groups ≥18 years in mid-June) | | | | | | | | | |
| 18–64 years | Unvaccinated | 268 | Ref | 220 | Ref | 48 | Ref | 4 | Ref |
| Fully vaccinated | 47 | 1.179 (0.830–1.675) | 37 | 0.959 (0.666–1.379) | 10 | 0.471 (0.153–1.221) | 5 | 1.058 (0.146–6.497) |
| Partially and fully vaccinated | 84 | **1.372 (1.056–1.783)** | 71 | 1.150 (0.876–1.511) | 13 | 0.478 (0.202–1.026) | 6 | 1.039 (0.187–5.372) |
| Including all patients hospitalised after a positive SARS-CoV-2 test, regardless of main cause of hospitalisation | | | | | | | | | |
| 18–79 years | Unvaccinated | 2422 | Ref | 2014 | Ref | 408 | Ref | 80 | Ref |
| Fully vaccinated | 151 | **1.353 (1.067–1.715)** | 128 | 1.133 (0.880–1.459) | 23 | **0.571 (0.326–0.955)** | 18 | 1.234 (0.596–2.393) |
| ≥80 years | Unvaccinated | 72 | Ref | 66 | Ref | 6 | Ref | 20 | Ref |
| Fully vaccinated | 116 | 1.120 (0.829–1.515) | 108 | 1.017 (0.744–1.391) | 8 | 0.559 (0.163–1.892) | 14 | **0.237 (0.094–0.561)** |
| ≥18 years | Unvaccinated | 2494 | Ref | 2080 | Ref | 414 | Ref | 100 | Ref |
| Fully vaccinated | 267 | **1.356 (1.137–1.617)** | 236 | 1.161 (0.962–1.400) | 31 | **0.622 (0.395–0.952)** | 32 | **0.537 (0.317–0.888)** |
| Excluding fully vaccinated patients with >150 days between date of last dose and positive test | | | | | | | | | |
| 18–79 years | Unvaccinated | 2057 | Ref | 1672 | Ref | 385 | Ref | 68 | Ref |
| Fully vaccinated | 89 | **1.391 (1.082–1.790)** | 76 | 1.040 (0.796–1.359) | 13 | **0.431 (0.218–0.789)** | 10 | 1.161 (0.507–2.423) |
| ≥80 years | Unvaccinated | 51 | Ref | 48 | Ref | 3 | Ref | 10 | Ref |
| Fully vaccinated | 26 | 1.603 (0.987–2.603) | 26 | 1.383 (0.852–2.244) | 0 | - | 3 | 0.497 (0.099–1.911) |
| ≥18 years | Unvaccinated | 2108 | Ref | 1720 | Ref | 388 | Ref | 78 | Ref |
| Fully vaccinated | 115 | **1.437 (1.148–1.798)** | 102 | 1.067 (0.841–1.354) | 13 | **0.427 (0.217–0.778)** | 13 | 0.791 (0.378–1.545) |
| Excluding all time between hospital stays in calculating total length of stay (in the main analysis we included time between stays as part of the patient’s length of stay, if the time between two consecutive stays was less than 24 hours, to allow for transfers between hospitals). | | | | | | | | | |
| 18–79 years | Unvaccinated | 2057 | Ref | 1672 | Ref | - | - | - | - |
| Fully vaccinated | 109 | **1.354 (1.068–1.716)** | 89 | 1.174 (0.909–1.517) | - | - | - | - |
| ≥80 years | Unvaccinated | 51 | Ref | 48 | Ref | - | - | - | - |
| Fully vaccinated | 74 | 1.174 (0.809–1.705) | 69 | 1.184 (0.812–1.725) | - | - | - | - |
| ≥18 years | Unvaccinated | 2108 | Ref | 1720 | Ref | - | - | - | - |
| Fully vaccinated | 183 | **1.399 (1.140–1.718)** | 158 | 1.170 (0.941–1.456) | - | - | - | - |
| Including deaths up to 7 days post-discharge b in analysis of odds for mortality, instead of only death in hospital as in the main analysis. Only patients discharged by 14 October are included to ensure 7 days of follow-up. | | | | | | | | | |
| ≥80 years | Unvaccinated | - | - | - | - | - | - | 13 | Ref |
| Fully vaccinated | - | - | - | - | - | - | 12 | 0.584 (0.204–1.648) |
| ≥18 years | Unvaccinated | - | - | - | - | - | - | 80 | Ref |
| Fully vaccinated | - | - | - | - | - | - | 24 | 0.711 (0.382–1.282) |

ICU: Intensive care unit; 95%CI: 95% confidence interval. Bold text = statistically significant results.

a Excludes patients who were still admitted to ICU at the end of the study period, or who passed away in ICU.

b Six additional patients died up to 7 days post-discharge, all of whom were ≥80 years

## 3. Distribution of vaccine type in the study cohort

*Table S2: Distribution of vaccine type among vaccinated SARS-CoV-2 patients in the study cohort*

|  |  |  |
| --- | --- | --- |
| Vaccine type | Partially vaccinated a | Fully vaccinated |
| Comirnaty | 59 | 167 |
| Spikevax | 11 | 11 |
| Comirnaty + Spikevax | - | 1 |
| Vaxzevria + Comirnaty | - | 3 |
| Previous COVID-19 infection + Comirnaty | - | 1 |
| Total | 70 | 183 |

a 8 partially vaccinated patients had received their second dose <7 days before positive SARS-CoV-2 test. All received a second dose of Comirnaty.

*Table S3: Distribution of time between doses in weeks among SARS-CoV-2 patients fully vaccinated with two doses of a COVID-19 vaccine in the study cohort*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Vaccine type | | | |
| Number of weeks between doses | Comirnaty | Spikevax | Comirnaty + Spikevax | Vaxzevria + Comirnaty |
| <3 a | 2 | 0 | 0 | 0 |
| 3 | 95 | 0 | 0 | 0 |
| 4 | 8 | 6 | 0 | 0 |
| 5 | 5 | 0 | 0 | 0 |
| 6 | 50 | 4 | 0 | 0 |
| 7 | 4 | 1 | 0 | 0 |
| 8 | 1 | 0 | 1 | 0 |
| 9 | 1 | 0 | 0 | 0 |
| 10 | 1 | 0 | 0 | 1 |
| 11 | 0 | 0 | 0 | 1 |
| 12 | 0 | 0 | 0 | 1 |
| Total | 167 | 11 | 1 | 3 |

a Dose interval of 19 or 20 days, as per the absolute minimum interval between doses for Comirnaty (4)

## 4. References

1. Norwegian Institute of Public Health. Påvisning og overvåkning av SARS-CoV 2-virusvarianter. 2021 [cited 2021 Nov 4]. Available from: <https://www.fhi.no/nettpub/coronavirus/testing/pavisning-og-overvakning-av-sars-cov-2-virusvarianter/>.

2. Veneti L, Seppala E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. PLoS One. 2021;16(10):e0258513.

3. Norwegian Institute of Public Health. Vaccination scenario. 2021 [cited 2021 Nov 4]. Available from: <https://www.fhi.no/en/publ/posters/vaksineringsscenario/>

4. Norwegian Institute of Public Health. Vanlige problemstillinger om koronasertifikat. 2021 [cited 2021 Nov 4]. Available from: <https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/>